Fig. 3From: Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patientsDifferences in hospital costs of patients with DPYD variants compared to patients without a variant (after adjusting for confounding)Back to article page